Le produit a bien été ajouté au panier.

discount label
Bivalirudin
Vue en 3D

Biosynth logo

Bivalirudin

Ref. 3D-PP49896

1mg
248,00 €
10mg
292,00 €
100mg
481,00 €
Livraison estimée en/au États-Unis, le vendredi 27 décembre 2024

Informations sur le produit

Nom :
Bivalirudin
Description :

Peptide Bivalirudin is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Bivalirudin include the following: Clot-targeted micellar formulation improves anticoagulation efficacy of bivalirudin ZG She , X Liu , VR Kotamraju, E Ruoslahti - ACS nano, 2014 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/nn502947b A systematic review and meta-analysis of bivalirudin application in peripheral endovascular procedures Y Hu , AY Liu, L Zhang, X Wu, S Shi, JR Elmore - Journal of Vascular , 2019 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0741521419301818 Quantitation of bivalirudin, a novel anticoagulant peptide, in human plasma by LC-MS/MS: method development, validation and application to XJ Li, YT Sun, L Yin, XJ Zhang, Y Yang - Journal of , 2013 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2095177912001220 Bivalirudin inhibits periprocedural platelet function and tissue factor expression of human smooth muscle cells W Pepke, A Eisenreich, M Jaster, Y Ayral - Cardiovascular , 2013 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1755-5922.2011.00305.x Bivalirudin decreases NO bioavailability by vascular immobilization of myeloperoxidase V Rudolph, TK Rudolph, FJ Schopfer , G Bonacci - of Pharmacology and , 2008 - ASPEThttps://jpet.aspetjournals.org/content/327/2/324.short Pharmacology and clinical use of bivalirudin TM Sciulli, VF Mauro - Annals of Pharmacotherapy, 2002 - journals.sagepub.comhttps://journals.sagepub.com/doi/abs/10.1345/aph.1A197 Bivalirudin: a review TE Warkentin, A Koster - Expert Opinion on Pharmacotherapy, 2005 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14656566.6.8.1349 Bivalirudin TE Warkentin, A Greinacher - Thrombosis and , 2008 - thieme-connect.comhttps://www.thieme-connect.com/products/ejournals/abstract/10.1160/TH07-10-0644 Bivalent direct thrombin inhibitors: hirudin and bivalirudin TE Warkentin - Best Practice & Research Clinical Haematology, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1521692604000039 Influence of bivalirudin on tissue factor-triggered coagulation T Orfeo, KE Brummel-Ziedins - Blood coagulation & , 2007 - journals.lww.comhttps://journals.lww.com/bloodcoagulation/FullText/2007/07000/Influence_of_bivalirudin_on_tissue.4.aspx Bivalirudin in percutaneous coronary intervention SJ Lehman, DP Chew - Vascular Health and Risk Management, 2006 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.2147/vhrm.s24357 Bivalirudin: a new generation antithrombotic drug R Scatena - Expert Opinion on Investigational Drugs, 2000 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/13543784.9.5.1119 Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender R Robson, H White, P Aylward - Clinical Pharmacology , 2002 - Wiley Online Libraryhttps://ascpt.onlinelibrary.wiley.com/doi/abs/10.1067/mcp.2002.124522 Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin P Eichler, N Lubenow , U Strobel, A Greinacher - Blood, 2004 - ashpublications.orghttps://ashpublications.org/blood/article-abstract/103/2/613/17854 Storage stability of bivalirudin: hydrophilic versus lipophilic solutions O Zupančič , JA Griessinger, HT Lam - Journal of , 2017 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S0022354917300229 Bivalirudin: pharmacology and clinical applications NW Shammas - Cardiovascular drug reviews, 2005 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1527-3466.2005.tb00177.x Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides NK Kapur, C Shenoy , AA Yunis, NN Mohammad - PLoS , 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0034344 Bivalirudin: in patients with ST-segment elevation myocardial infarction MP Curran - Drugs, 2010 - Springerhttps://link.springer.com/article/10.2165/11205120-000000000-00000 Bivalirudin in percutaneous coronary intervention MF Caron, GR McKendall - American journal of health-system , 2003 - academic.oup.comhttps://academic.oup.com/ajhp/article-abstract/60/18/1841/5143009 Clinical pharmacology of bivalirudin MD Reed , D Bell - : The Journal of Human Pharmacology and , 2002 - Wiley Online Libraryhttps://accpjournals.onlinelibrary.wiley.com/doi/abs/10.1592/phco.22.10.105S.33616 Bivalirudin: a review of its use in patients undergoing percutaneous coronary intervention MD Moen, GM Keating, K Wellington - Drugs, 2005 - Springerhttps://link.springer.com/article/10.2165/00003495-200565130-00010 Bivalirudin during percutaneous coronary intervention in acute coronary syndromes M Laine , G Lemesle , T Dabry, V Panagides - Expert opinion on , 2019 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/14656566.2018.1551361 Bivalirudin in acute coronary syndromes M Galli , M Bernardi , L Ortega-Paz , R Nerla - Expert Review of , 2023 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/14779072.2023.2273902 Safety of bivalirudin in patients with coronary artery disease M Abdel-Wahab, G Richardt - Expert Opinion on Drug Safety, 2012 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14740338.2012.628312 , reverse phase ultra-high performance liquid chromatographic method for related substances of a therapeutic peptide (bivalirudin trifluoroacetate) using the quality by KYK Kumar, VR Dama, C Suchitra, TC Maringanti - Analytical methods, 2020 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2020/ay/c9ay01998g Development of a Novel Separation Technique by High Performance Liquid Chromatography for the Determination of Bivalirudin KMM Gulzar, S Atul, S Surana - Journal of analytical chemistry, 2019 - Springerhttps://link.springer.com/article/10.1134/S1061934819100071 Liquid chromatography-high resolution mass spectrometry for peptide drug quality control K Zeng, I Geerlof-Vidavisky, A Gucinski , X Jiang - The AAPS Journal, 2015 - Springerhttps://link.springer.com/article/10.1208/s12248-015-9730-z Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions HD White, DP Chew - Expert Opinion on Pharmacotherapy, 2002 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1517/14656566.3.6.777 MMP9-sensitive polymers mediate environmentally-responsive bivalirudin release and thrombin inhibition DS Chu, DL Sellers , MJ Bocek , AE Fischedick - Biomaterials , 2015 - pubs.rsc.orghttps://pubs.rsc.org/en/content/articlehtml/2015/bm/c4bm00259h Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures DP Chew - Hamostaseologie, 2002 - thieme-connect.comhttps://www.thieme-connect.com/products/ejournals/html/10.1055/s-0037-1619549 Clinical outcomes of bivalirudin for ischemic heart disease DF Kong, EJ Topol , JA Bittl, HD White, P Théroux - Circulation, 1999 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/01.cir.100.20.2049 Bivalirudin: a review of the pharmacology and clinical application DA Van De Car, SV Rao, EM Ohman - Expert review of , 2010 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1586/erc.10.158 Liquid chromatography method for determination of bivalirudin in human plasma and urine using automated ortho-phthalaldehyde derivatization and fluorescence D Farthing , T Larus, I Fakhry, T Gehr, J Prats - of Chromatography B, 2004 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S157002320301016X Bivalirudin: a review of its potential place in the management of acute coronary syndromes CI Carswell, GL Plosker - Drugs, 2002 - Springerhttps://link.springer.com/article/10.2165/00003495-200262050-00008 Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention C Kimmelstiel, P Zhang, NK Kapur - Circulation , 2011 - Am Heart Assochttps://www.ahajournals.org/doi/abs/10.1161/circinterventions.110.959098 Safety and effectiveness of bivalirudin in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis AH Ahmad Hamdi, AF Dali , TH Mat Nuri - Frontiers in , 2017 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fphar.2017.00410/full Bivalirudin monitored with the ecarin clotting time for anticoagulation during cardiopulmonary bypass A Koster, D Chew, M Grundel, M Bauer - Anesthesia & , 2003 - journals.lww.comhttps://journals.lww.com/anesthesia-analgesia/FullText/2003/02000/Bivalirudin_Monitored_with_the_Ecarin_Clotting.15.aspx

Avis:
Nos produits sont destinés uniquement à un usage en laboratoire. Pour tout autre usage, veuillez nous contacter.
Marque:
Biosynth
Stockage à long terme :
Notes :

Propriétés chimiques

MDL:
Point de fusion :
Point d'ébullition :
Point d'éclair :
Densité :
Concentration :
EINECS :
Merck :
Code SH :

Informations sur les risques

Numéro ONU :
EQ:
Classe :
Phrases R :
Phrases S :
Transport aérien interdit :
Informations sur les risques :
Groupe d'emballage :
LQ :

Question d’ordre technique sur : 3D-PP49896 Bivalirudin

Veuillez plutôt utiliser le panier afin de demander un devis ou passer commande

Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages

* Champ obligatoire
Bienvenue chez CymitQuimica !Nous utilisons des cookies pour améliorer votre visite. Nous n’incluons pas de publicité.

Veuillez consulter notre Politique de Cookies pour plus de détails ou ajustez vos préférences dans "Configurer".